Comparison between ABP 234 and Keytruda® (Pembrolizumab)
20210033
Phase 1 other active
Quick answer
Comparison between ABP 234 and Keytruda® (Pembrolizumab) for Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer is a Phase 1 program (other) at Amgen Technology (Ireland) UC with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Amgen Technology (Ireland) UC
- Indication
- Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
- Phase
- Phase 1
- Modality
- other
- Status
- active